Disease relevance of Osteitis Deformans

• We determined the response of 1alpha,25-dihydroxyvitamin D3 after mithramycin-induced hypocalcemia in eight subjects with polyostotic Paget's disease of bone [1].
• Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight - day for 6 to 24 months [2].
• Mutations in the gene encoding p62 cause Paget's disease of bone (PDB), a common disorder of the elderly characterized by excessive bone resorption and formation [3].
• Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry [4].
• The EIA detected increased Pyd & Dpd concentrations in urine from postmenopausal women and patients with osteoporosis, hyperthyroidism, hyperparathyroidism, and Paget disease of bone [5].

Psychiatry related information on Osteitis Deformans

• Similarly, mutations in the valosin-containing protein (VCP) gene have been shown to cause inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia [6].

High impact information on Osteitis Deformans

• We identified two heterozygous insertion mutations in exon 1 of TNFRSF11A in affected members of four families with FEO or familial Paget disease of bone (PDB) [7].
• In untreated patients with severe Paget's disease of bone or hyperphosphatasia (urinary Hyp greater than 2.0 micronmol/mg creatinine) urinary Hyl/Hyp averaged 0.052+/-0.042 (0.042+/-0.009 in normal bone) and Hy1(G1cGa1)/Hy1(Ga1) 0.601+/-0.017 (0.47+/-0.009 in normal bone) [8].
• Hazards of gallium for Paget's disease of bone [9].
• Intravenous clodronate in the treatment and retreatment of Paget's disease of bone [10].
• Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease [11].

Chemical compound and disease context of Osteitis Deformans

• Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone [12].
• Etidronate disodium in the treatment of Paget's disease of bone [13].
• Mithramycin and long remission of Paget's disease of bone [14].
• CONCLUSIONS: Short-term treatment with gallium nitrate can reduce biochemical parameters of disease activity in patients with advanced Paget disease of bone [15].
• Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis [15].

Biological context of Osteitis Deformans

• Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree [16].
• Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone [17].
• Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent [18].
• Cytogenetic investigations of patients on clodronate therapy for Paget's disease of bone [19].
• Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate [20].

Anatomical context of Osteitis Deformans

• Multicentric giant cell tumor with viral-like inclusions associated with Paget's disease of bone: a case treated by steroid therapy [21].

Gene context of Osteitis Deformans

• These studies confirm that mutations affecting the ubiquitin-binding domain of SQSTM1 are a common cause of familial and sporadic Paget's disease of bone [22].
• Here we demonstrate that amylin has a hypocalcemic effect in patients with Paget's disease of bone [23].
• Frequencies of HLA-A and HLA-B histocompatibility antigens in Paget's disease of bone [24].
• Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates [25].
• In order to determine the prevalence of secondary hyperparathyroidism in patients with Paget's disease of bone, we measured serum parathyroid hormone levels (N-terminal assay) in 39 patients with a wide range of pagetic activity [26].

Analytical, diagnostic and therapeutic context of Osteitis Deformans

• Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone [27].
• We measured BPS in 36 patients with Paget's disease of bone, both before and 6 months after treatment with intravenous APD (disodium pamidronate) infusions [28].
• We report a randomized placebo-controlled double-blind study of amino-hydroxybutylidene bisphosphonate (alendronate), infused over 1 h, in 15 patients with Paget's disease of bone [29].
• Bone scintigraphy following intravenous pamidronate for Paget's disease of bone [30].
• This study assessed the efficacy of 200 mg of aminohexane bisphosphonate (neridronate) administered by intravenous infusion in a single dose or in two separate doses on consecutive days in 32 patients (16 males and 16 females, average age 66 years) affected by active Paget's disease of bone [31].

References